New Insights on the Long-Term Safety of ENJAYMO® in Cold Agglutinin Disease Presented at ASH 2025 Recordati Rare Diseases unveils long-term safety data of ENJAYMO® (sutimlimab-jome) for cold agglutinin disease at the ASH Annual Meeting.

New Insights on the Long-Term Safety of ENJAYMO® in Cold Agglutinin Disease Presented at ASH 2025 #USA #Bridgewater #Recordati #ENJAYMO #Cold_Agglutinin_Disease